Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Allergy, Asthma & Clinical Immunology
Published in: Allergy, Asthma & Clinical Immunology 1/2018

Open Access 01-12-2018 | Research

Loss of bronchoprotection to Salbutamol during sputum induction with hypertonic saline: implications for asthma therapy

Authors: Hongyu Wang, Melanie Kjarsgaard, Terence Ho, John D. Brannan, Parameswaran Nair

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2018

Login to get access

Abstract

Background

Sputum induction with hypertonic saline in obstructive airway diseases is generally safe. However, saline induces bronchoconstriction in some patients despite pre-medication with Salbutamol. Our objectives were to investigate the predictors of failure of Salbutamol to protect against saline-induced-bronchoconstriction in patients with asthma and COPD and to evaluate implications for asthma therapy.

Methods

Retrospective survey on a database of 3565 patients with obstructive airway diseases who had sputum induced with hypertonic saline. The effect of baseline FEV1, bronchitis and concomitant medication on saline-induced-bronchoconstriction (≥ 15% drop in FEV1) were examined by logistic regression analysis. A subgroup had this re-examined 8–12 weeks after decreasing long-acting-beta-2-agonist dose or after adding Montelukast, which included an assessment of mast cell activity in sputum.

Results

222 (6.2%) patients had saline-induced-bronchoconstriction despite pre-treatment with inhaled Salbutamol. Baseline airflow obstruction (FEV1% predicted < 60% OR 3.29, p < 0.001) and long-acting-beta-agonist use (OR 2.02, p = 0.001), but not bronchitis, were predictors of saline-induced-bronchoconstriction, which decreased when long-acting-beta-agonist dose was decreased. Refractoriness to subsequent bronchodilation was associated with mast cell activity and was attenuated by Montelukast.

Conclusion

Sputum induction with saline provides information on bronchitis and additional physiological data on tolerance to beta-agonists and mast cell activity that may have implications for clinical therapy.
Literature
1.
Vlachos-Mayer H, Leigh R, Sharon RF, Hussack P, Hargreave FE. Success and safety of sputum induction in the clinical setting. Eur Respir J. 2000;16(5):997–1000.CrossRefPubMed
2.
ten Brinke A, de Lange C, Zwinderman AH, Rabe KF, Sterk PJ, Bel EH. Sputum induction in severe asthma by a standardized protocol. Am J Respir Crit Care Med. 2001;164(5):749–53.CrossRefPubMed
3.
Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med. 1995;152(3):838–60.CrossRefPubMed
4.
Haney S, Hancox RJ. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial. Respir Res. 2005;6(1):1–7.CrossRef
5.
Jabbal S, Manoharan A, Lipworth BJ. Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma. Clin Exp Allergy. 2017;163:44–7.
6.
Zuhlke IE, Kanniess F, Richter K, Nielsen-Gode D, Bohme S, Jorres RA, et al. Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD. Eur Respir J. 2003;22(6):926–30.CrossRefPubMed
7.
Pizzichini E, Pizzichini MMM, Efthimiadis AE, Evans S, Morris MM, Squillace D, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996;154:308–17.CrossRefPubMed
8.
Cockcroft DW, Berscheid BA. Standardization of inhalation provocation tests. Chest. 1982;82(5):572–5.CrossRefPubMed
9.
Coates AL, Wanger J, Cockcroft DW, Culver BH, the Bronchoprovocation Testing Task Force, Carlsen KH, Diamant Z, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017;49(5):1601526.CrossRefPubMed
10.
Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur Respir J. 2001;17(3):368–73.CrossRefPubMed
11.
Hancox RJ, Aldridge RE, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, et al. Tolerance to beta-agonists during acute bronchoconstriction. Eur Respir J. 1999;14(2):283–7.CrossRefPubMed
12.
Haney S, Hancox RJ. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med. 2005;99(5):566–71.CrossRefPubMed
13.
Lipworth BJ, Aziz I. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. J Allergy Clin Immunol. 1999;103(1):88–92.CrossRefPubMed
14.
Swystun VA, Gordon JR, Davis EB, Zhang X, Cockcroft DW. Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. J Allergy Clin Immunol. 2000;106(1):57–64.CrossRefPubMed
15.
Hekking P-P, Loza MJ, Pavlidis S, de Meulder B, Lefaudeux D, Baribaud F, et al. Pathway discovery using transcriptomic profiles in adult-onset severe asthma. J Allergy Clin Immunol. 2017;141(4):1280–90.CrossRefPubMed
16.
Berthon BS, Gibson PG, Wood LG, MacDonald-Wicks LK, Baines KJ. A sputum gene expression signature predicts oral corticosteroid response in asthma. Eur Respir J. 2017;49(6):1700180.CrossRefPubMed
Metadata
Title
Loss of bronchoprotection to Salbutamol during sputum induction with hypertonic saline: implications for asthma therapy
Authors
Hongyu Wang
Melanie Kjarsgaard
Terence Ho
John D. Brannan
Parameswaran Nair
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Allergy, Asthma & Clinical Immunology / Issue 1/2018
Electronic ISSN: 1710-1492
DOI
https://doi.org/10.1186/s13223-018-0256-7

Other articles of this Issue 1/2018

Allergy, Asthma & Clinical Immunology 1/2018 Go to the issue

Case report

First-reported pediatric cases of American ginseng anaphylaxis and allergy

Research

Regular follow-up visits reduce the risk for asthma exacerbation requiring admission in Korean adults with asthma

Research

Seasonal variation in circulating group 2 innate lymphoid cells in mugwort-allergic asthmatics during and outside pollen season

Research

Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)

Correction

Correction to: Passive blood anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction

Short report

Dose omission to shorten methacholine challenge testing: clinical consequences of the use of a 10% fall in FEV1 threshold